Fox News
The drug has been shown to be less effective than some rivals but has milder side effects and analysts say it could find favor among newly diagnosed patients. Around 35 percent to 40 percent of multiple sclerosis (MS) sufferers prefer to take no...
Reuters
Topics Sanofi CEO Christopher Viehbacher addresses the Boston College's Chief Executives Club of Boston in Massachusetts March 6, 2012. French drugmaker Sanofi SA gained U.S. approval for its multiple sclerosis pill, Aubagio, on Wednesday -- one of...
Boston Globe
The positive ruling for the Cambridge biotechnology company's therapy, called Aubagio, marks the Food and Drug Administration's first approval of a Genzyme drug since French pharmaceutical giant Sanofi SA bought Genzyme for $20.1 billion in 2010.